C

Coya Therapeutics Inc
NASDAQ:COYA

Watchlist Manager
Coya Therapeutics Inc
NASDAQ:COYA
Watchlist
Price: 7.2194 USD -0.28%
Market Cap: 109.9m USD
Have any thoughts about
Coya Therapeutics Inc?
Write Note

Intrinsic Value

COYA's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one COYA stock under the Base Case scenario is 5.5223 USD. Compared to the current market price of 7.2194 USD, Coya Therapeutics Inc is Overvalued by 24%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

COYA Intrinsic Value
5.5223 USD
Overvaluation 24%
Intrinsic Value
Price
C
Worst Case
Base Case
Best Case

Valuation Backtest
Coya Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for COYA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about COYA?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Coya Therapeutics Inc

Provide an overview of the primary business activities
of Coya Therapeutics Inc.

What unique competitive advantages
does Coya Therapeutics Inc hold over its rivals?

What risks and challenges
does Coya Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Coya Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Coya Therapeutics Inc.

Provide P/S
for Coya Therapeutics Inc.

Provide P/E
for Coya Therapeutics Inc.

Provide P/OCF
for Coya Therapeutics Inc.

Provide P/FCFE
for Coya Therapeutics Inc.

Provide P/B
for Coya Therapeutics Inc.

Provide EV/S
for Coya Therapeutics Inc.

Provide EV/GP
for Coya Therapeutics Inc.

Provide EV/EBITDA
for Coya Therapeutics Inc.

Provide EV/EBIT
for Coya Therapeutics Inc.

Provide EV/OCF
for Coya Therapeutics Inc.

Provide EV/FCFF
for Coya Therapeutics Inc.

Provide EV/IC
for Coya Therapeutics Inc.

Show me price targets
for Coya Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Coya Therapeutics Inc?

How accurate were the past Revenue estimates
for Coya Therapeutics Inc?

What are the Net Income projections
for Coya Therapeutics Inc?

How accurate were the past Net Income estimates
for Coya Therapeutics Inc?

What are the EPS projections
for Coya Therapeutics Inc?

How accurate were the past EPS estimates
for Coya Therapeutics Inc?

What are the EBIT projections
for Coya Therapeutics Inc?

How accurate were the past EBIT estimates
for Coya Therapeutics Inc?

Compare the revenue forecasts
for Coya Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Coya Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Coya Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Coya Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Coya Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Coya Therapeutics Inc with its peers.

Analyze the financial leverage
of Coya Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Coya Therapeutics Inc.

Provide ROE
for Coya Therapeutics Inc.

Provide ROA
for Coya Therapeutics Inc.

Provide ROIC
for Coya Therapeutics Inc.

Provide ROCE
for Coya Therapeutics Inc.

Provide Gross Margin
for Coya Therapeutics Inc.

Provide Operating Margin
for Coya Therapeutics Inc.

Provide Net Margin
for Coya Therapeutics Inc.

Provide FCF Margin
for Coya Therapeutics Inc.

Show all solvency ratios
for Coya Therapeutics Inc.

Provide D/E Ratio
for Coya Therapeutics Inc.

Provide D/A Ratio
for Coya Therapeutics Inc.

Provide Interest Coverage Ratio
for Coya Therapeutics Inc.

Provide Altman Z-Score Ratio
for Coya Therapeutics Inc.

Provide Quick Ratio
for Coya Therapeutics Inc.

Provide Current Ratio
for Coya Therapeutics Inc.

Provide Cash Ratio
for Coya Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Coya Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Coya Therapeutics Inc?

What is the current Free Cash Flow
of Coya Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Coya Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Coya Therapeutics Inc

Current Assets 39.9m
Cash & Short-Term Investments 36.6m
Other Current Assets 3.3m
Non-Current Assets 52.3k
PP&E 52.3k
Current Liabilities 3.8m
Accounts Payable 1.9m
Accrued Liabilities 1m
Other Current Liabilities 939k
Non-Current Liabilities 856.7k
Other Non-Current Liabilities 856.7k
Efficiency

Earnings Waterfall
Coya Therapeutics Inc

Revenue
9.6m USD
Operating Expenses
-19.8m USD
Operating Income
-10.2m USD
Other Expenses
148.2k USD
Net Income
-10.1m USD

Free Cash Flow Analysis
Coya Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

COYA Profitability Score
Profitability Due Diligence

Coya Therapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

Positive Revenue Growth Forecast
Negative Operating Income
Negative Net Income
Negative ROE
24/100
Profitability
Score

Coya Therapeutics Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.

COYA Solvency Score
Solvency Due Diligence

Coya Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Coya Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

COYA Price Targets Summary
Coya Therapeutics Inc

Wall Street analysts forecast COYA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for COYA is 15.9375 USD with a low forecast of 14.14 USD and a high forecast of 18.9 USD.

Lowest
Price Target
14.14 USD
96% Upside
Average
Price Target
15.9375 USD
121% Upside
Highest
Price Target
18.9 USD
162% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for COYA?

Click here to dive deeper.

Dividends

Coya Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for COYA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

COYA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

COYA News

Other Videos

Profile

Coya Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

109.9m USD

Dividend Yield

0%

Description

Coya Therapeutics, Inc. is a clinical-stage biotechnology company engaged in developing approaches utilizing Treg modifying therapeutics to target systemic and neuro inflammation. The company is headquartered in Houston, Texas. The company went IPO on 2022-12-29. The firm is focused on developing new therapies to enhance the function of regulatory T cells (Tregs). The company is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases. The company has a diversified product candidate pipeline that includes both ex vivo (outside the body) and in vivo (inside the body) therapeutic approaches intended to restore the suppressive and immunomodulatory functions of Tregs. Its 300 Series product candidates include COYA 301 and COYA 302, its 200 Series product candidates include COYA 201 and COYA 206, and its 100 Series product candidate is COYA 101. Its COYA 301 is a biologic for subcutaneous administration. Its COYA 302 is a combination of two molecules for subcutaneous and/or intravenous administration. Its COYA 201 product candidate utilizes its Treg-derived exosome therapeutic modality. Its COYA 101 is its autologous regulatory T-cell product candidate.

Contact

TEXAS
Houston
5850 San Felipe St., Suite 500
+8005878170
www.coyatherapeutics.com

IPO

2022-12-29

Employees

-

Officers

Chairman & CEO
Dr. Howard Berman Ph.D.
President & Chief Medical Officer
Dr. Fred Grossman D.O., FAPA
CFO & COO
Mr. David S. Snyder
Chief Technical Officer
Dr. Gregory MacMichael Ph.D.
Senior Vice President of Regulatory Affairs
Dr. Michelle Frazier Ph.D.
Head of Neuroinflammation Platform
Mr. Aaron Thome Ph.D.
Show More
Chief Business Development Officer
Dr. Arun Swaminathan Ph.D.
Senior VP of Program Management & Clinical Operations
Ms. Karen King M.S.
Show Less

See Also

Discover More
What is the Intrinsic Value of one COYA stock?

The intrinsic value of one COYA stock under the Base Case scenario is 5.5223 USD.

Is COYA stock undervalued or overvalued?

Compared to the current market price of 7.2194 USD, Coya Therapeutics Inc is Overvalued by 24%.

Back to Top